211Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy

Human Gene Therapy

Volumn 26, Issue 6, 2015, Pages 399-406

  Burtner, Christopher R ^a   Chandrasekaran, Devikha ^a   Santos, Erlinda B ^a   Beard, Brian C ^a,b   Adair, Jennifer E ^a,b   Hamlin, Donald K ^c   Wilbur, D Scott ^c   Sandmaier, Brenda M ^a,b   Kiem, Hans Peter ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BISMUTH 213; CARMUSTINE; CD34 ANTIBODY; CREATININE; GAMMA GLUTAMYLTRANSFERASE; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45 AT 211; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ASTATINE; CD45 ANTIGEN; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANINE MODEL; CELL COUNT; CELL ISOLATION; CELL LOSS; CONJUGATION; CREATININE BLOOD LEVEL; CYTOTOXICITY; DNA MODIFICATION; ISOTOPE LABELING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; STEM CELL GENE THERAPY; UREA NITROGEN BLOOD LEVEL; WHOLE BODY RADIATION; ANIMAL; CHEMISTRY; DOG; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; TRANSGENE; TRANSPLANTATION CONDITIONING;

CANIS FAMILIARIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; ASTATINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOGS; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; TRANSGENES; TRANSPLANTATION CONDITIONING; TUMOR SUPPRESSOR PROTEINS;

EID: 84932622724     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.021     Document Type: Article

References (29)

1. Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? (Review). J Allergy Clin Immunol 2013;131:994-1000.
2. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014;312:48-56.
3. Pagel JM, Matthews DC, Appelbaum FR, et al. The use of radioimmunoconjugates in stem cell transplantation (Mini-review). Bone Marrow Transplant 2002;29:807-816.
4. Appelbaum FR, Matthews DC, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992;54:829-833.
5. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001;98:565-572.
6. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
7. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
8. Palanca-Wessels MC, Press OW. Advances in the treatment of hematologic malignancies using immunoconjugates (Review). Blood 2014;123:2293-2301.
9. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988;240:1024-1026.
10. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-1239.
11. Orozco JJ, Back T, Kenoyer A, et al. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood 2013;121:3759-3767.
12. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells (Review). Annu Rev Immunol 2003;21:107-137.
13. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014;124:344-353.
14. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002;100:318-326.
15. Chen Y, Kornblit B, Hamlin DK, et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012;119:1130-1138.
16. Davis BM, Roth JC, Liu L, et al. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther 1999;10:2769-2778.
17. Adair JE, Beard BC, Trobridge GD, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med 2012;4:133ra57
18. Neff T, Beard BC, Peterson LJ, et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005;105:997-1002.
19. Beard BC, Sud R, Keyser KA, et al. Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood 2009;113:5094-5103.
20. Beard BC, Trobridge GD, Ironside C, et al. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 2010;120:2345-2354.
21. Wilbur DS, Chyan M-K, Nakamae H, et al. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconjugate Chem 2012;23:409-420.
22. 2. Nucl Med Biol 1993;20:917-927.
23. Horn PA, Keyser KA, Peterson LJ, et al. Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 2004;103:3710-3716.
24. Gori JL, Beard BC, Williams NP, et al. In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate. J Gene Med 2013;15:233-241.
25. Kiraly F, Kletting P, Reske S, Glatting G. Modelling radioimmunotherapy with anti-CD45 antibody to obtain a more favourable biodistribution. Nucl Med 2009;48:113-119.
26. Neff T, Horn PA, Peterson LJ, et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003;112:1581-1588.
27. Gori JL, Beard BC, Ironside C, et al. In vivo selection of autologous MGMT gene-modified cells following-reduced intensity conditioning with BCNU and temozolomide in the dog model. Cancer Gene Ther 2012;19:523-529.
28. Nakamae H, Wilbur DS, Hamlin DK, et al. Biodistribution, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211. Cancer Res 2009;69:2408-2415.
29. Barquinero J, Kiem H-P, von Kalle C, et al. Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. Blood 1995;85:1195-1201.